Wang Huan, Wang Xuejun, Ju Yanfang, Wang Jinliang, Zhang Xin, Cheng Yao, Sun Jing, Hu Yi
Department of Oncology, The General Hospital of PLA, Beijing 100853, P.R. China.
Department of Neurology, Qinghai Women Children's Hospital, Xining, Qinghai 810000, P.R. China.
Exp Ther Med. 2014 Jan;7(1):185-190. doi: 10.3892/etm.2013.1408. Epub 2013 Nov 13.
The aim of this study was to evaluate the effects of treatment and the factors influencing the postoperative recurrence and survival time for pseudomyxoma peritonei (PMP). A total of 39 patients with PMP who received treatment were analyzed in The General Hospital of PLA (Beijing, China) between 2002 and 2011. The patients received cytoreductive surgery (CRS) and 25 cases of PMP recurred. Seven patients received postoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). The median follow-up was 40 months. There were eight mortalities in this period. The 5- and 10-year survival rates were 89.0 and 35.0%, respectively. The medians of overall survival (OS) and recurrence time were 37 and 4 months, respectively. Multivariate analyses revealed that pathological subtype was able to influence the recurrence (P=0.042) and OS (P=0.033) times, as an independent prognostic factor. HIPEC was significantly associated with postoperative recurrence time (P=0.017). Patients with disseminated peritoneal adenomucinosis had a more favorable prognosis. CRS combined with HIPEC was able to extend the postoperative recurrence time for patients with PMP.
本研究旨在评估腹膜假黏液瘤（PMP）的治疗效果以及影响术后复发和生存时间的因素。2002年至2011年期间，解放军总医院（中国北京）对39例接受治疗的PMP患者进行了分析。患者接受了减瘤手术（CRS），其中25例PMP复发。7例患者接受了术后腹腔热灌注化疗（HIPEC）。中位随访时间为40个月。在此期间有8例死亡。5年和10年生存率分别为89.0%和35.0%。总生存（OS）和复发时间的中位数分别为37个月和4个月。多因素分析显示，病理亚型作为独立的预后因素，能够影响复发（P=0.042）和OS（P=0.033）时间。HIPEC与术后复发时间显著相关（P=0.017）。弥漫性腹膜腺黏液瘤患者的预后较好。CRS联合HIPEC能够延长PMP患者的术后复发时间。
